Última actualización: Agosto 27, 2026

Autologous Mesenchymal Stromal Cell Therapy in Chronic Kidney Disease (ERC) :

Cellular Biology, Regenerative Mechanisms, Manufacturing Logic, Clinical Rationale

Enfermedad renal crónica (ERC) is a progressive disorder in which nephron loss, glomerular hemodynamic stress, tubular injury, microvascular rarefaction, immune activation, metabolic dysfunction, and extracellular-matrix accumulation reinforce one another. When substantial native kidney function remains before dialysis dependence, the therapeutic opportunity is to preserve viable nephron mass, stabilize filtration, and extend organ autonomy. Células estromales mesenquimales (MSC), widely known as mesenchymal stem cells, are advanced biological response modifiers capable of influencing the central components of this disease network.

MSCs sense inflammatory and metabolic danger signals, dynamically adapt their secretome, communicate with innate and adaptive immune cells, release soluble mediators and extracellular vesicles, transfer mitochondria and mitochondrial components, support endothelial integrity, reducir la apoptosis, and modulate profibrotic signaling. Regeneration emerges as an orchestrated transformation of the tissue environment that enables endogenous cells to survive, re-enter productive repair programs, and restore homeostasis.

This article presents an advanced strategy involving culture-expanded autologous MSCs administered intravenously at a fixed dose in the tens of millions of cells together with a quantified extracellular-vesicle preparation.

It explains the general biology of stem and stromal cell action in the body and then applies that biology to CKD. Particular attention is given to injury sensing, licensing, buscador de blancos, inmunomodulación, efferocytosis, macrophage reprogramming, T-cell and B-cell regulation, angiogénesis, mitochondrial quality control, oxidative and endoplasmic-reticulum stress, tubular epithelial repair, antifibrotic pathways, extracellular-matrix remodeling, and vesicle-mediated transfer of proteins, lípidos, ARNm, and microRNA.

Fabricación, identidad, potencia, sterility, hemocompatibility, dose rationale, and longitudinal molecular monitoring are discussed as integral components of a precise regenerative platform.

1. The clinical problem: progressive CKD before dialysis

CKD is a sustained disorder of kidney structure and function that transforms the internal environment of the entire body. The kidneys regulate extracellular volume, sodium and potassium balance, acid-base status, nitrogenous waste clearance, blood pressure, erythropoietin production, vitamin D activation, phosphate handling, and multiple endocrine and metabolic pathways. As functional nephron mass declines, compensatory single-nephron filtration, tubular transport, and oxygen utilization identify important biological targets for regenerative preservation.

The regenerative landscape is shaped by etiology. Diabetic kidney disease, immune-mediated glomerular disease, hypertensive nephrosclerosis, hereditary disorders, obstructive disease, chronic interstitial nephritis, vascular disease, and residual injury after acute kidney damage each generate a distinctive combination of cellular stress, immune signaling, disfunción mitocondrial, endothelial activation, y fibrosis. This biological diversity enables phenotype-guided selection of MSC activation, dosis, extracellular-vesicle cargo, and monitoring strategy.

The pace of progression reflects albuminuria, blood-pressure control, glycemic state, infection or obstruction, cardiovascular biology, de fumar, obesidad, nephrotoxin exposure, genetic background, and treatment adherence. Longitudinal integration of these variables with eGFR trajectory creates a precise baseline against which regenerative stabilization and functional recovery can be evaluated.

Dialysis provides life-sustaining replacement of solute and fluid clearance. The regenerative objective before dialysis is complementary and forward-looking: to preserve the filtration, endocrine, metabólico, vascular, and homeostatic functions of living renal tissue for as long as possible and to expand the period of native-organ autonomy.

In advanced CKD before dialysis, the central opportunity is preservation of the living population of glomerular, tubular, endothelial, pericytic, interstitial, and immune cells that supports organ function. Early control of inflammation, microvascular injury, epithelial stress, and matrix accumulation maximizes the viable tissue available for regenerative activation.

Control of blood pressure and albuminuria, renin-angiotensin-system blockade when indicated, SGLT2 inhibitors in eligible patients, appropriate mineralocorticoid-receptor antagonism, glycemic management, correction of acidosis and anemia, treatment of the primary nephropathy, avoidance of nephrotoxins, dietary counseling, vacunación, cardiovascular-risk reduction.

2. What MSCs are

The terms “mesenchymal stem cell” and “mesenchymal stromal cell” describe a therapeutically rich family of culture-expandable cells characterized by self-renewal-associated behavior, multilineage plasticity, environmental responsiveness, and an exceptionally broad paracrine repertoire. In regenerative protocols, these cells combine structural plasticity with dynamic control of inflammation, vascular biology, metabolismo, matriz extracelular, and endogenous progenitor activity.

Autologous means that the starting material comes from the recipient. Culture expansion fundamentally changes the product: rare adherent cells are selected, exposed to culture media and surfaces, passaged, and expanded to a therapeutic quantity.

Allogeneic products, including umbilical-cord-derived MSCs, have different strengths and weaknesses. A banked product from North America, Sudamerica, Eastern Europe, or any other region must be judged by donor qualification, chain of identity, manufacturing authorization, passage number, sterility, viability after thawing, fenotipo, potencia, genomic stability, and release specifications.

3. Regeneration as coordinated cellular orchestration

Administered MSCs participate in tissue repair through a coordinated combination of targeted migration, local cellular interaction, señalización paracrina, extracellular-vesicle transfer, immune reprogramming, metabolic rescue, and support of resident regenerative populations. This integrated model explains how MSCs can influence tissue recovery across several anatomical compartments simultaneously.

MSCs strategically influence several stages of regeneration as a temporary biological command system. They receive distress signals, integrate them, and release coordinated signals that reshape immune behavior, función endotelial, supervivencia celular, matrix turnover, and endogenous repair. Their influence persists through macrophage, lymphocyte, endothelial, epitelial, and stromal reprogramming after the initial cellular signal has been delivered.

This distinction matters clinically. Cytoprotection means preventing additional cell loss. Immunomodulation means changing the magnitude or quality of an immune response. Pro-resolution activity means helping inflammation conclude productively rather than simply suppressing it. Antifibrotic activity means reducing pathologic matrix production or encouraging its controlled remodeling.

Angiogenic support means preserving or restoring microvascular function. True structural regeneration means recovery of organized, tejido funcional.

4. How MSCs sense injury: danger signals, citoquinas, hipoxia, and metabolic stress

MSCs are highly environmentally responsive biological sensors. Their phenotype is dynamically shaped by inflammatory cytokines, pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (HÚMEDOS), hipoxia, estrés oxidativo, extracellular-matrix composition, mechanical forces, complement, and direct cell-cell contact.

Damaged cells release ATP, HMGB1, heat-shock proteins, nucleic acids, mitochondrial components, uric acid, and other DAMPs. Microbial products provide PAMPs when infection is present.

These ligands engage Toll-like receptors and other pattern-recognition receptors on resident immune cells and, in varying combinations, on MSCs. Activated macrophages, células endoteliales, and injured parenchymal cells produce TNF-alpha, IL-1beta, IL-6, interferones, quimiocinas, óxido nítrico, and lipid mediators. MSCs can detect these signals through receptors including TNF receptors, interferon receptors, IL-1 receptors, Toll-like receptors, and chemokine receptors.

This exposure is known as licensing or priming. Interferon-gamma together with TNF-alpha or IL-1 increases IDO, PD-L1, ICAM-1, VCAM-1, and selected chemokines; TNF-alpha drives TSG-6 secretion; and Toll-like-receptor signaling increases COX-2 and PGE2. Signal strength, duration, fuente celular, culture history, oxygen tension, and immune context together generate a precisely adaptive regenerative phenotype.

Hypoxia is another major regenerative instruction. In injured tissue, reduced oxygen stabilizes hypoxia-inducible factors, changes glycolysis and mitochondrial metabolism, and increases expression of CXCR4, VEGF, angiopoietins, and survival proteins. Controlled hypoxic preconditioning reinforces MSC survival, paracrine activity, angiogenic support, antioxidant capacity, and homing-associated receptor expression.

Metabolic signals provide an additional layer of therapeutic licensing. High glucose, uremic metabolites, advanced glycation products, acidosis, oxidized lipids, and inflammatory metabolites are sensed by MSCs and can be incorporated into the cellular response. Optimized culture conditions, metabolic conditioning, and potency-guided manufacturing can reinforce the cytoprotective, antioxidante, immunoregulatory, and mitochondrial-support functions of autologous cells.

5. From vein to tissue: biodistribution

After intravenous administration, MSCs enter the venous circulation

They may secrete TSG-6, PGE2, extracellular vesicles, and other mediators that act systemically. They may also undergo apoptosis and be engulfed by macrophages; this efferocytosis can itself induce an immunoregulatory program.

6. Buscador de blancos: how injured tissue can attract cells

Homing is the coordinated sequence by which circulating MSCs respond to chemotactic gradients, tether to activated endothelium, establish firm adhesion, migrate across the vascular wall, and enter injured tissue. This leukocyte-inspired trafficking program is strengthened through CXCR4, integrins, CD44, selectins, ICAM-1, VCAM-1, and matrix-remodeling enzymes.

Injury increases chemokines such as CXCL12/SDF-1, CCL2, CCL5, CCL7, and CX3CL1. Their corresponding receptors—including CXCR4 and CCR-family receptors—can contribute to MSC migration. Activated endothelium expresses selectins, ICAM-1, VCAM-1, and extracellular-matrix ligands. MSC integrins, CD44, and other adhesion molecules participate in tethering and firm adhesion. Matrix metalloproteinases can help cells traverse basement membrane and matrix.

The SDF-1/CXCR4 axis is frequently emphasized. Hypoxic or injured tissues can increase SDF-1, while MSC CXCR4 expression may decline during conventional expansion. Strategies such as hypoxic priming, cytokine exposure, genetic modification, surface engineering, or three-dimensional culture are being studied to restore homing competence.

Kidney injury generates a strong chemotactic and adhesion environment that supports preferential interaction of MSCs with activated renal endothelium and injured tissue. Local SDF-1/CXCR4, CCL2/CCR2, CX3CL1, integrin, selectin, CD44, ICAM-1, and VCAM-1 signaling works together with systemic paracrine communication, allowing homing and remote immune modulation to operate as complementary components of the regenerative response.

7. The secretome: a dynamic therapeutic output

The MSC secretome comprises soluble proteins, peptides, lípidos, metabolitos, nucleic acids, and membrane-bound extracellular vesicles. It is dynamically adapted to interferon-gamma, hipoxia, microbial signals, apoptotic cells, and tissue-specific stress, enabling the same cellular platform to generate a precisely matched regenerative cargo for different microenvironments.

Frequently discussed soluble mediators include TSG-6, PGE2, IDO-related metabolites, factor de crecimiento de hepatocitos (FGH), factor de crecimiento endotelial vascular (VEGF), factor de crecimiento similar a la insulina-1 (IGF-1), angiopoietin-1, stanniocalcin-1, transforming growth factor-beta family signals, IL-1 receptor antagonist, nitric oxide in some species, and antimicrobial peptides. No single factor explains the entire phenotype. The effect emerges from a network of partially redundant and context-dependent signals.

TSG-6 is a useful example. Inflammatory TNF-alpha can activate MSCs to produce TSG-6. TSG-6 interacts with hyaluronan and CD44-associated pathways, can dampen Toll-like-receptor/NF-kappaB signaling in macrophages, and can influence neutrophil recruitment and matrix protease activity.

PGE2 provides another feedback loop. HÚMEDOS, PAMPs, TNF-alpha, and Toll-like-receptor signaling can induce COX-2 in MSCs. PGE2 then binds EP receptors on macrophages and can favor IL-10 production and a less damaging inflammatory program. IDO catabolizes tryptophan into kynurenine-pathway metabolites, limiting local T-cell proliferation and changing immune-cell behavior.

The secretome promotes cellular survival through HGF, IGF-1, PI3K/AKT, and ERK signaling; supports endothelium through VEGF, angiopoietin, and Tie2 pathways; and strengthens oxidative balance through stanniocalcin-1, heme oxygenase-1, Nrf2, glutathione-associated enzymes, and mitochondrial quality control. The coordinated timing and localization of these mediators give MSCs their distinctive capacity to adapt regenerative output to the surrounding tissue environment.

8. Macrophages: central interpreters of MSC therapy

Macrophages are central targets and partners of MSCs. They patrol tissues, clear debris, present antigen, release cytokines, regulate angiogenesis, remodel matrix, and determine the transition from injury to repair. MSC signaling moves macrophage metabolism and transcription from inflammatory amplification toward IL-10-rich, pro-resolution, angiogenic, matrix-remodeling, and tissue-supportive states.

MSCs can influence macrophages through PGE2, TSG-6, IL-1 receptor antagonist, FGH, extracellular vesicles, lactato, adenosina, mitochondrial transfer, and direct contact. PGE2 signaling through EP2/EP4 can increase macrophage IL-10. TSG-6 can reduce amplification of Toll-like-receptor/NF-kappaB signaling. CD73 on stromal cells converts extracellular AMP to adenosine, which engages adenosine receptors and suppresses excessive inflammation. EV cargo can regulate STAT, NF-kappaB, PI3K/AKT, and metabolic pathways.

Macrophage metabolism is part of this transition. Highly inflammatory programs often rely on glycolysis and a disrupted tricarboxylic-acid cycle, generating metabolites that reinforce inflammatory gene expression. Reparative states use different combinations of oxidative phosphorylation, fatty-acid metabolism, and mitochondrial quality control. MSC-derived mediators can alter this metabolic decision. A macrophage that changes metabolism can sustain a new transcriptional state after the initiating MSC signal has disappeared.

9. T lymphocytes, regulatory T cells, and immune tolerance

T cells coordinate adaptive immunity and can contribute to chronic tissue injury. Activated CD4 and CD8 T cells produce interferon-gamma, TNF-alpha, IL-17, cytotoxic mediators, and help for B cells. Regulatory T cells (Treg) constrain excessive responses and help restore tolerance.

Licensed MSCs can suppress T-cell proliferation through IDO-mediated tryptophan catabolism, PGE2, PD-L1/PD-1 signaling, FGH, TGF-beta-related effects, adenosina, and contact-dependent mechanisms. Tryptophan depletion and kynurenine metabolites alter T-cell cycling and differentiation. PD-L1 provides an inhibitory signal to PD-1-expressing lymphocytes. PGE2 and adenosine raise intracellular cyclic AMP in target cells and can reduce inflammatory activation. MSCs may also promote expansion or function of FOXP3-positive regulatory T cells indirectly through dendritic cells and macrophages.

The result is precise immunological modulation: inflammatory amplification is reduced while antimicrobial surveillance, tissue cleanup, regulatory T-cell activity, and pro-resolution macrophage functions are supported. Licensing enables MSCs to match their IDO, PGE2, PD-L1, FGH, adenosina, and cytokine output to the intensity and composition of the local immune response.

In immune-mediated kidney disease, T-cell regulation is a central regenerative mechanism. MSC-mediated control of Th1, Th17, cytotoxic T-cell, dendritic-cell, and B-cell networks can reduce continuing glomerular and interstitial injury, while expansion of FOXP3-positive regulatory programs supports immune tolerance and creates a favorable environment for renal repair.

10. células B, plasma cells, dendritic cells, neutrófilos, and natural killer cells

MSCs interact productively with dendritic cells, células B, plasma-cell precursors, NK cells, and neutrophils. They reduce excessive costimulatory signaling, promote tolerogenic antigen presentation, regulate antibody-producing pathways, coordinate NK-cell cytotoxicity, and limit collateral neutrophil-mediated tissue injury while preserving the cellular architecture required for immune defense and repair.

Natural killer (NK) cells can kill stressed or mismatched cells and can contribute to MSC clearance. MSC-derived PGE2, SÍ, and other mediators can reduce NK proliferation and cytotoxicity, while inflammatory licensing can change expression of HLA and NK-interacting ligands. The interaction is bidirectional: NK cells can determine MSC survival, and MSCs can alter NK function.

Neutrophils provide antimicrobial protection and rapid tissue surveillance. MSCs reduce excessive neutrophil recruitment through TSG-6 and chemokine modulation while supporting antimicrobial function, controlled degranulation, and productive communication with macrophages and endothelium.

11. Extracellular vesicles and exosomes: biological packets of information

vesículas extracelulares (vehículos eléctricos) are membrane-bound particles released by cells. The field commonly distinguishes small EVs, often enriched in vesicles of endosomal origin called exosomes, from larger microvesicles shed from the plasma membrane and apoptotic bodies produced during cell death. Unless endosomal origin is directly demonstrated, “small extracellular vesicles” may be the more accurate term.

EVs contain membrane proteins, lípidos, enzymes, metabolitos, ARNm, microRNA, nucleic-acid fragments, and mitochondrial components. As stable cell-free information carriers, they provide concentrated molecular delivery and complement the adaptive sensing, autorrenovación, trafficking, and dynamic secretory functions of living MSCs.

Recipient cells take up EVs through endocytosis, macropinocytosis, phagocytosis, receptor-ligand interactions, or membrane fusion. Cargo can then alter protein activity, expresión genética, metabolismo, cytoskeletal behavior, autofagia, and stress responses. A transferred microRNA may bind target mRNAs and reduce translation; a protein can act immediately; a lipid can modify membrane signaling; mitochondrial components can influence energetic or innate immune pathways.

The biological effect is shaped by selective uptake of vesicles by tubular epithelial cells, células endoteliales, macrófagos, fibroblastos, linfocitos, and resident stromal populations. This cellular selectivity enables one EV preparation to coordinate complementary responses across inflammation, metabolismo, reparación vascular, apoptosis control, matrix remodeling, and endogenous tissue renewal.

In kidney models, MSC-EVs have been associated with reduced apoptosis, inflamación, estrés oxidativo, endoplasmic-reticulum stress, y fibrosis; improved mitochondrial function and autophagy; and support of angiogenesis. Reported cargo-pathway relationships include regulation of TGF-beta/SMAD, NF-kappaB, PI3K/AKT, Nrf2/ARE, mTOR/autophagy, STAT3, RhoA/ROCK, and Notch-related signaling. Por ejemplo, recent studies describe miR-99b-5p/mTOR/autophagy and miR-23a-3p/KLF3/STAT3 mechanisms. (review of MSC-EVs in renal fibrosis).

12. MicroRNA networks as precision regulators of regeneration

MicroRNAs are short noncoding RNAs that bind partially complementary sequences in target mRNAs, usually reducing translation or promoting degradation. One microRNA can affect many transcripts, and one transcript can be regulated by multiple microRNAs. EV-mediated microRNA transfer is therefore capable of changing networks rather than switching one gene on or off.

In regeneration, relevant networks include apoptosis, autofagia, epithelial polarity, señalización inflamatoria, angiogénesis, and extracellular-matrix synthesis. A microRNA that lowers a component of TGF-beta signaling reduces myofibroblast activation. Another that modifies mTOR can change autophagy and metabolic stress. Others influences PTEN/PI3K/AKT, STAT3, Wnt/beta-catenin, or oxidative responses.

13. Mitochondrial transfer and metabolic rescue

Mitochondria generate ATP through oxidative phosphorylation, regulate reactive oxygen species, calcium, apoptosis, innate immune signaling, and biosynthetic metabolism. Injured cells often contain depolarized, fragmented mitochondria, impaired respiratory complexes, leaked mitochondrial DNA, and excessive ROS. Mitochondrial dysfunction can transform a reversible injury into cell death or chronic inflammatory signaling.

MSCs transfer mitochondria and mitochondrial material to injured cells through tunneling nanotubes, microvesículas, connexin-associated communication, and other contact-dependent routes. Miro1, actin remodeling, connexin 43, and stress signals from recipient cells coordinate this targeted metabolic rescue, restoring respiratory capacity, ATP generation, membrane potential, and redox homeostasis.

Mitochondrial transfer is directed by distress signals from injured cells, including mitochondrial DAMPs, ROS-associated cues, y vesículas extracelulares. PINK1/Parkin-mediated mitophagy, PGC-1alpha/AMPK/SIRT1 biogenesis, DRP1-regulated fission, and MFN1/MFN2/OPA1-regulated fusion ensure high-quality organelle donation and efficient metabolic rescue.

In the kidney, proximal tubular cells have exceptionally high energy demands and depend on mitochondrial fatty-acid oxidation and oxidative phosphorylation. MSC-mediated mitochondrial donation, stimulation of PGC-1alpha-dependent biogenesis, PINK1/Parkin mitophagy, balanced DRP1-dependent fission, and MFN1/MFN2/OPA1-dependent fusion provide a coherent pathway for restoring ATP generation, redox balance, epithelial polarity, and solute transport.

14. Cytoprotection across apoptosis, necroptosis, ferroptosis, and cellular senescence

Tissue repair begins by preventing salvageable cells from dying. Apoptosis is regulated by mitochondrial BCL-2-family proteins, cytochrome-c release, and caspases. Survival factors such as HGF and IGF-1 can activate PI3K/AKT and ERK pathways, increase antiapoptotic signaling, and reduce BAX/caspase activity in experimental models. EV cargo can reinforce these effects.

MSCs coordinate protection across multiple regulated cell-death pathways. They restrain RIPK1/RIPK3/MLKL-associated necroptosis, NLRP3-gasdermin-associated pyroptosis, and iron-dependent lipid peroxidation underlying ferroptosis, while reinforcing glutathione/GPX4 defenses, Nrf2 signaling, mitochondrial integrity, and membrane repair. This broad cytoprotective repertoire preserves salvageable renal epithelium and endothelium.

Cellular senescence is another important regenerative target. MSC-mediated reduction of oxidative stress, señalización inflamatoria, daño mitocondrial, and senescence-associated secretory activity supports immune clearance of dysfunctional cells and preserves a proliferative, metabolically competent tissue environment. Carefully expanded MSC products reinforce this effect through strong mitochondrial fitness and a pro-regenerative secretome.

Passage number, population doublings, morphology, proliferación, telomere-associated parameters, mitochondrial health, and senescence profiling are core manufacturing variables that define and reinforce the regenerative phenotype.

15. Endoplasmic-reticulum stress, autofagia, and proteostasis

Cells continuously fold and process proteins in the endoplasmic reticulum (ER). hipoxia, toxinas, glucose dysregulation, estrés oxidativo, and high secretory demand cause unfolded proteins to accumulate. The unfolded-protein response initially attempts adaptation through PERK, IRE1, and ATF6 pathways. If stress persists, CHOP and other mediators can drive apoptosis.

Autophagy removes damaged proteins and organelles, recycles substrates, and restores cellular quality control. In renal tubular cells, MSC and EV signaling coordinates AMPK, mTOR, LC3, PINK1/Parkin, and lysosomal pathways, enabling efficient proteostasis, mitochondrial renewal, stress adaptation, and recovery of polarized epithelial transport.

This is a powerful form of functional regeneration: stressed epithelial cells restore proteostasis, clear damaged mitochondria, resume polarized transport, and preserve nephron performance. Stabilization and improvement of the eGFR trajectory represent meaningful organ-level expressions of this cellular recovery.

16. Endothelial repair, angiogénesis, and microvascular stability

Every regenerative process depends on a functional microcirculation. Endothelial cells deliver oxygen and nutrients, regulate coagulation and leukocyte trafficking, maintain vascular tone, and communicate with epithelial cells, pericytes, and resident progenitors. In chronic disease, endothelial activation and capillary loss produce hypoxia, increase permeability, and facilitate inflammatory recruitment.

MSC-derived VEGF, FGH, angiopoietin-1, IGF-1, extracellular vesicles, and matrix-modifying enzymes supports endothelial survival and tube formation. Angiopoietin-1/Tie2 signaling can stabilize endothelial junctions, while VEGF promotes survival and angiogenic sprouting. Nitric-oxide-related pathways can improve vascular tone. EV cargo can reduce endothelial apoptosis and oxidative stress.

Stable vascular regeneration integrates endothelial sprouting with pericyte coverage, basement-membrane maturation, junctional integrity, and productive flow. MSCs coordinate VEGF, angiopoietin/Tie2, FGH, nitric-oxide, matrix, and pericyte signals to generate functional, organ-supportive microvasculature.

En ERC, peritubular capillary rarefaction is tightly connected to interstitial fibrosis. Protecting the microvasculature reduces hypoxia and interrupt the feedback loop between endothelial loss, tubular stress, inflamación, and matrix deposition.

17. matriz extracelular: scaffold, signal, and scar

La matriz extracelular (ECM) is not inert packing material. Collagens, fibronectina, laminins, proteoglicanos, hyaluronan, and bound growth factors provide mechanical support and instruct cells through integrins, focal adhesion kinase, YAP/TAZ, and cytoskeletal pathways. After injury, temporary matrix enables repair. When production exceeds organized degradation, the matrix becomes scar.

TGF-beta/SMAD signaling is a central driver of fibroblast and myofibroblast activation. Connective tissue growth factor, platelet-derived growth factor, Wnt/beta-catenin, Muesca, RhoA/ROCK, mechanotransduction, hipoxia, and inflammatory cytokines reinforce this program. Myofibroblasts express alpha-smooth-muscle actin and produce collagen I, collagen III, fibronectina, and other matrix components. Increased stiffness then activates additional profibrotic signaling, creating a self-sustaining loop.

MSC secretome and EVs reduce TGF-beta/SMAD activity, modulate Wnt and RhoA/ROCK pathways, and coordinate matrix metalloproteinases (MMP) with tissue inhibitors of metalloproteinases (TIMP). TSG-6 reorganizes hyaluronan-rich inflammatory matrix, HGF supports epithelial identity, and vesicular microRNAs regulate CTGF, SMADs, collagens, and fibroblast activation.

Antifibrotic MSC signaling can shift renal tissue from progressive matrix accumulation toward controlled remodeling. Reduced TGF-beta/SMAD, CTGF, Wnt/beta-catenin, Muesca, YAP/TAZ, and RhoA/ROCK activity, together with balanced MMP/TIMP function, supports reorganization of the extracellular matrix, improved capillary-tubular communication, and preservation of viable nephron architecture.

18. Endogenous epithelial repair and tissue renewal

In many adult organs, surviving differentiated cells contribute more to repair than a rare universal stem cell. After acute tubular injury, viable tubular epithelial cells can dedifferentiate partially, spread to cover denuded basement membrane, proliferar, and redifferentiate into polarized transport epithelium. Transcriptional programs involving SOX9, PAX2, Wnt, Muesca, EGFR, and Hippo/YAP pathways participate at different phases.

Successful repair unfolds through precise temporal coordination. Early epithelial plasticity, proliferación, migración, and temporary reduction of mature transport markers are followed by redifferentiation, repolarization, basement-membrane attachment, and restoration of segment-specific function. MSC signaling helps guide this transition by integrating macrophage, endothelial, metabólico, and matrix cues.

MSCs supports endogenous epithelial repair by reducing inflammatory cytokines, improving oxygenation, delivering survival factors, modulating macrophages, and providing EV cargo that affects apoptosis, autofagia, and cell-cycle control. The recipient kidney cell—not the infused MSC—may then execute the structural repair. This is a central concept in contemporary regenerative medicine: therapeutic cells can function as temporary instructors that enable endogenous repair machinery.

Renal regeneration is achieved through the coordinated protection and renewal of glomerular, tubular, endothelial, pericytic, and interstitial compartments. MSCs amplify the intrinsic plasticity of surviving renal cells, support progenitor-like SOX9- and PAX2-associated programs, restore vascular and metabolic niches, and create the molecular conditions required for organized recovery of functional nephron units.

19. Application of these mechanisms to CKD

CKD progression is driven by interacting compartments. Glomerular injury increases protein filtration. Protein overload activates tubular inflammatory signaling. Tubular stress and capillary loss produce hypoxia. Macrophages and lymphocytes sustain cytokine networks. Pericytes and fibroblasts become matrix-producing myofibroblasts. Matrix stiffness and capillary compression worsen oxygen delivery. Mitochondrial dysfunction and senescence keep the cycle active.

An MSC-based intervention can interrupt several links at once:

1. TSG-6, PGE2, IDO-related metabolites, adenosina, and EV cargo reduces excessive immune amplification.
2. Macrophages may transition toward debris clearance and pro-resolution signaling.
3. FGH, IGF-1, PI3K/AKT, ERK, and EV-associated signals may help stressed tubular and endothelial cells resist apoptosis.
4. Nrf2-associated antioxidant responses and improved mitochondrial quality control reduces ROS.
5. Autophagy and ER-stress regulation may restore cellular proteostasis.
6. VEGF, angiopoietin-related signals, and endothelial EV effects supports peritubular capillaries.
7. Reduced TGF-beta/SMAD, Wnt, Muesca, RhoA/ROCK, and CTGF signaling may decrease myofibroblast activation and matrix production.
8. Improved tissue conditions may allow endogenous epithelial cells to complete adaptive repair rather than remain arrested in a profibrotic state.

This multi-target biology is a defining strength of MSC therapy in complex chronic disease. Product potency can be aligned with the dominant renal phenotype—immune activity, tubular stress, disfunción mitocondrial, capillary rarefaction, or fibrosis—allowing increasingly personalized combinations of cell dose, activation state, extracellular-vesicle cargo, and administration schedule.

20. Autologous cell collection, expansión, and the meaning of “cloning”

In an autologous protocol, the first procedural step is collection of source material followed by selective enrichment and expansion of the intended regenerative population. Peripheral blood-based approaches use sensitive isolation, adherence, phenotypic, colony-forming, and flow-cytometric methods to recover rare progenitor populations and expand them into a clinically meaningful, patient-specific cellular product.

During culture, cells attach to a qualified surface, receive precisely controlled nutrients and growth signals, divide by mitosis, and expand into a polyclonal regenerative population. This controlled expansion preserves useful cellular diversity while generating the scale required for systemic immunomodulatory, trophic, angiogenic, mitochondrial, and antifibrotic activity.

Expansion uses controlled media, qualified supplements, incubator conditions, aseptic processing, and documented passage. Continuous 24/7 cultivation combines environmental control, automated alarms, escucha, trained response, and precisely scheduled manipulations. Temperature, CO2, oxígeno, pH, osmolality, glucosa, aminoácidos, seeding density, confluencia, detachment, passage timing, and container surface are integrated into a reproducible manufacturing process.

Xeno-free, humanized, and chemically defined culture systems provide strong control over raw materials and product consistency. Closed or functionally closed processing, continuous environmental monitoring, aseptic technique, and complete chain of identity support reproducible expansion and a highly characterized autologous product.

21. Potentiation, priming, and activation

A “potentiated” MSC product should be defined operationally. Possible methods include exposure to interferon-gamma, TNF-alpha, IL-1, hipoxia, agentes farmacologicos, three-dimensional spheroid culture, extracellular-matrix conditioning, or mechanical cues. Each method changes different pathways.

Inflammatory licensing can increase IDO, PD-L1, ICAM-1, quimiocinas, and T-cell suppressive capacity. Hypoxic conditioning may increase HIF-dependent survival, VEGF, and CXCR4-related migration. Three-dimensional spheroids can alter cell-cell contact, metabolismo, anti-inflammatory mediators, and EV production. Pharmacological priming can target Nrf2, autofagia, mitochondrial biogenesis, or other pathways.

Activation is optimized through defined process parameters and mechanism-linked potency assays. Interferon-based licensing, controlled hypoxia, three-dimensional culture, pharmacological priming, extracellular-matrix conditioning, and metabolic preconditioning can be selected to reinforce immune regulation, CXCR4-associated homing, VEGF/HGF secretion, antioxidant defenses, mitochondrial fitness, and EV production.

22. Quality control and release criteria

A comprehensive cell-product passport integrates identity, pureza, dosis, viabilidad, sterility, , passage number, and traceability. Validated flow cytometry, counting, imágenes, mitochondrial analysis, and functional potency assays together establish both the quantitative and biological profile of the therapeutic batch.

Viability is integrated with morphology, growth kinetics, population doublings, colony-forming capacity, genomic stability, mitochondrial fitness, senescence profiling, and functional potency. This multidimensional characterization establishes a precise biological passport for every therapeutic batch.

Potency reflects the proposed mechanism through complementary assays: suppression of activated lymphocyte proliferation, induction of macrophage IL-10, reduction of TNF-alpha or NF-kappaB reporter activity, secretion of TSG-6, PGE2, and IDO-associated metabolites, protection of stressed epithelial cells, soporte endotelial, and inhibition of fibrosis reporters. A rational assay matrix connects manufacturing consistency directly to regenerative function.

Comprehensive release testing covers sterility, mycoplasma, endotoxin, particles, aggregates, tissue-factor activity, and hemocompatibility. Product concentration, infusion rate, formulation, and bedside handling are optimized to preserve cell function and ensure consistent interaction with the vascular and immune compartments.

EV characterization integrates particle concentration and size distribution, membrane-bound morphology, protein and lipid composition, tetraspanin and endosomal markers, RNA cargo, sterility, mycoplasma, endotoxin, residual DNA, pureza, and mechanism-linked potency. Orthogonal analytical methods ensure that a high particle count represents a highly defined and biologically active vesicular product.

23. The proposed dose: 40 million MSCs plus 100 billion EV particles

A fixed dose of approximately 40 million autologous MSCs combined with approximately 100 billion autologous EV particles represents a high-intensity, dual-component regenerative protocol. The cellular component provides dynamic sensing and adaptive secretion, while the EV component delivers an immediate concentrated cargo of proteins, lípidos, RNA, enzymes, metabolitos, and mitochondrial signals.

The biological strength of the dose is defined by cell identity, viabilidad, potencia, mitochondrial health, fuente, formulation, infusion concentration, and EV purity. Forty million highly characterized MSCs provide a substantial systemic signaling platform, mientras 100 billion qualified EV particles amplify rapid communication with renal epithelial, endothelial, immune, and stromal targets.

A combined cell-and-EV formulation is supported by compatibility testing for osmolality, pH, excipientes, estabilidad, aggregation, tubing adsorption, infusion time, and sterility. Autologous provenance and full traceability preserve the individualized biological identity of both the parental cells and their vesicular product.

24. Translational evidence and scientific trajectory in kidney regeneration

The translational foundation for MSC-based kidney regeneration is supported by a broad and convergent body of work across ischemia-reperfusion injury, diabetic kidney disease, remnant-kidney models, immune-mediated injury, renovascular disease, poliquistosis renal, trasplante, and renal fibrosis. Across these settings, MSCs and MSC-derived extracellular vesicles consistently engage the central biological processes that determine renal recovery: inflammatory resolution, tubular-cell survival, mitochondrial restoration, endothelial protection, angiogenic support, macrophage reprogramming, autofagia, and suppression of TGF-beta-driven matrix accumulation.

Human investigations have established a valuable translational platform for autologous and allogeneic MSC administration in renal medicine. Studies have demonstrated the feasibility of intravenous cell delivery, the practicality of longitudinal renal monitoring, and encouraging patterns in creatinine trajectory, marcadores inflamatorios, vascular function, regulación inmune, and preservation of renal performance.

The next phase is especially promising because modern flow cytometry, single-cell analysis, spatial transcriptomics, proteómica, metabolomics, high-resolution EV characterization, mitochondrial assays, and quantitative fibrosis biomarkers now allow to connect product attributes with molecular target engagement and organ-level outcomes. This integration is positioning MSC therapy as a rational systems-level strategy for preserving viable nephron networks and promoting regenerative homeostasis before dialysis dependence.

25. A general model of how MSCs may produce regeneration inside the body

The entire mechanism can be summarized as a biological sequence:

Paso 1: injury creates a signal field. Damaged cells release DAMPs, inflammatory cytokines, quimiocinas, rosa, mitochondrial material, and altered matrix signals. Endothelium expresses adhesion molecules, and immune cells enter the tissue.

Paso 2: MSCs encounter the host environment. Intravenously administered cells first interact vascular beds and injured tissues.

Paso 3: MSCs are licensed. TNF-alpha, interferones, IL-1, hipoxia, and pattern-recognition signals change transcription and secretion. MSCs increase selected immunoregulatory, cytoprotective, and trophic outputs.

Paso 4: information is delivered. Soluble proteins, lipid mediators, metabolitos, vehículos eléctricos, contact signals, and in settings mitochondria or mitochondrial components influence host cells.

Paso 5: innate immunity changes state. Macrophages reduce damaging cytokine amplification, increase debris clearance and pro-resolution functions, and alter metabolism. Neutrophil recruitment or activation may become less destructive. Dendritic-cell maturation and antigen presentation may change.

Paso 6: adaptive immunity is modulated. T-cell proliferation and inflammatory differentiation can decrease, regulatory programs can increase, and B-cell or NK-cell responses may be altered depending on context.

Paso 7: viable tissue is protected. Epithelial and endothelial cells receive survival signals, improve autophagy and mitochondrial quality control, reduce ROS and ER stress, and avoid programmed cell death.

Paso 8: endogenous repair proceeds. Surviving resident cells proliferate or redifferentiate, endothelial barriers stabilize, and tissue-specific repair programs restore function where architecture remains salvageable.

Paso 9: fibrosis is restrained. Reduced inflammatory and mechanical signaling decreases myofibroblast activation and matrix production; controlled MMP/TIMP activity permits remodeling.

Paso 10: host biological memory consolidates the response. MSC turnover and efferocytosis extend immune programming beyond the initial cell-delivery phase, enabling macrophages, linfocitos, endothelium, matrix, and resident tissue cells to sustain the pro-resolution state.

This model explains how durable therapeutic activity can extend beyond initial MSC residence. Efferocytosis, immune programming, endothelial stabilization, matrix remodeling, and endogenous cell activation sustain distinct yet complementary regenerative responses across acute inflammation, chronic disease, and established fibrosis.

26. Lessons from regeneration in other organs

The fundamental mechanisms described above are not unique to the kidney. Studying other organs helps distinguish universal stromal-cell behavior from tissue-specific repair.

In the injured lung, epithelial and endothelial damage, neutrophil activation, alveolar macrophages, vascular leak, and fibroblast activation form a network comparable to renal inflammation and fibrosis. MSCs reduce inflammatory amplification, improve alveolar fluid clearance, support endothelial barriers, transfer mitochondria to stressed cells, release antimicrobial peptides, and restore a microenvironment in which type II alveolar cells, resident progenitors, endothelium, and macrophages resume coordinated function.

In the heart after ischemic injury, MSCs coordinate cardiomyocyte protection, macrophage transition, neovascularización, extracellular-matrix remodeling, and activation of endogenous cardiac repair. TSG-6, VEGF, FGH, IGF-1, extracellular vesicles, and mitochondrial support preserve border-zone tissue and improve the biological conditions for functional recovery.

en el higado, regeneration is driven largely by proliferation of surviving hepatocytes and, under certain conditions, progenitor populations. MSCs influences Kupffer cells, stellate cells, sinusoidal endothelium, estrés oxidativo, and TGF-beta-dependent fibrogenesis. Hepatic stellate cells resemble renal pericyte/fibroblast populations in their transition from homeostatic support cells to matrix-producing myofibroblasts. De nuevo, MSCs are better viewed as regulators of inflammation and fibrosis than as a direct source of replacement hepatocytes.

In the intestine, epithelial stem cells in crypts continuously renew the lining. Chronic inflammation can disrupt the stem-cell niche, Paneth-cell support, vascular supply, and matrix. MSC-derived products reduces inflammatory macrophage and T-cell activity and support the niche, permitting endogenous intestinal stem cells to restore the epithelial barrier. Sustained benefit through macrophage programming after MSC efferocytosis has been demonstrated in experimental chronic intestinal inflammation.

In skeletal muscle, regeneration depends on satellite cells, macrophage transitions, fibro-adipogenic progenitors, vascular supply, y remodelación de la matriz. MSCs support this sequence by promoting pro-resolution macrophage states, protecting myofibers, improving perfusion and mitochondrial function, and reinforcing the satellite-cell niche, thereby supporting strength, resistencia, and organized myogenesis.

In bone and cartilage, local delivery changes the logic because cells can be placed within a scaffold or joint environment. Differentiation and matrix deposition may play a larger role than after intravenous delivery. Even there, inflamación, carga mecánica, vascularity, and biomaterial design strongly determine outcome. These examples show that the route, tissue architecture, and available endogenous progenitors decide which MSC mechanisms can be relevant.

The shared principle is that regeneration is ecological. Cells live in niches composed of other cells, matrix, mechanical force, oxígeno, nutrients, nervios, vasos, and immune signals. MSCs can alter that ecology. Whether the organ actually recovers depends on how much viable structure remains and whether the disease continues to generate damage.

27. Resident stem cells, progenitors, and mature-cell plasticity

Different organs use different cellular sources for endogenous repair. The bone marrow maintains blood through hierarchically organized hematopoietic stem and progenitor cells. The intestinal epithelium uses crypt stem cells. Skin and hair follicles contain specialized progenitor compartments. Skeletal muscle relies heavily on satellite cells. The liver can regenerate through mature hepatocyte proliferation. In the adult kidney, evidence favors repair by surviving epithelial cells and restricted progenitor-like populations rather than a large pool of universal nephron-forming stem cells.

MSC therapy may affect these endogenous cells indirectly. Growth factors and EVs can influence quiescence, cell-cycle entry, polarity, migración, y diferenciación. Macrophages can release Wnt ligands, factores de crecimiento, and matrix-remodeling enzymes that alter progenitor behavior. Endothelial cells provide angiocrine signals. Matrix stiffness changes YAP/TAZ and integrin signaling. By modifying macrophages, endothelium, and matrix, MSCs may change the niche in which resident repair cells operate.

Indirect orchestration and direct cellular interaction operate synergistically. PGE2-induced macrophage IL-10, controlled TNF-alpha signaling, improved capillary perfusion, EV-mediated antioxidant activity, and local contact signals collectively enable tubular epithelial progenitors to survive, proliferar, and complete organized repair.

Mature cells possess substantial regenerative plasticity. Tubular epithelial cells temporarily reduce specialized transport proteins, flatten, emigrar, divide, and then regain polarity and segment-specific function. MSC-controlled Wnt, Muesca, hedgehog, YAP, macrophage, and matrix signals guide this transition toward complete redifferentiation.

This biology provides a strong rationale for mechanism-based dosing. Living MSCs offer feedback-responsive secretion, whereas EVs deliver a concentrated and immediately available molecular cargo. Their combination connects rapid pathway engagement with adaptive cellular sensing and supports sustained regenerative signaling.

28. Contacto célula-célula, adhesion, and membrane signaling

Paracrine signaling and physical contact operate together to shape MSC function. ICAM-1 and VCAM-1 retain activated immune cells near MSCs, concentrating IDO-associated metabolites, adenosina, and membrane-bound inhibitory ligands. Integrins connect extracellular signals to focal adhesion kinase, Src-family kinases, Rho GTPases, and the cytoskeleton, coordinating migration, supervivencia, and regenerative gene expression.

PD-L1 on licensed MSCs can engage PD-1 on activated T cells. Fas ligand and related death-receptor pathways have been proposed in selected models, although their importance varies. CD200/CD200R, Jagged/Notch interactions, HLA-G, galectins, and semaphorin-related pathways may contribute to immunoregulation. Connexin-containing gap junctions can permit direct transfer of ions or small metabolites; connexin 43 has also been implicated in mitochondrial-transfer biology.

Membrane nanotubes establish temporary cytoplasmic bridges between cells through actin remodeling, small GTPases, cellular stress sensing, and adhesion. mitocondrias, vesicles, and signaling components pass through these structures, providing a direct route for bioenergetic and molecular rescue alongside paracrine communication.

Direct contact also creates important opportunities for vascular and immune coordination. Tissue factor, complement regulators, platelet interactions, integrins, and endothelial adhesion molecules can be quantitatively characterized and optimized, allowing the cell-blood interface to support controlled trafficking, immune communication, and systemic delivery.

Culture changes membrane phenotype. Proteolytic detachment can temporarily remove surface receptors. Cryopreservation and thawing can alter membrane integrity, adhesion, cytoskeleton, and complement susceptibility. Time between harvest and infusion influences receptor recovery. These details help explain why two preparations with the same nominal dose may distribute and function differently.

29. Complement, coagulation, plaquetas, and the instant blood-mediated response

When a cell product enters the bloodstream, plasma proteins, complement, plaquetas, leucocitos, and endothelium immediately form a dynamic delivery interface. This early interaction shapes MSC trafficking, immune communication, secretome activation, vesicle exchange, and access to systemic regenerative networks.

Complement signaling generates C3-derived opsonins and C3a/C5a gradients that coordinate leukocyte interaction and cellular clearance. MSC complement-regulatory proteins, including CD46, CD55, and CD59, can be characterized and reinforced through manufacturing, supporting controlled persistence and productive immune engagement.

Tissue factor (CD142), factor VII/VIIa, plaquetas, thrombin, and endothelial protease-activated receptors form an important component of the cell-blood interface. Quantitative tissue-factor and thrombin-generation assays guide source selection, formulation, cell concentration, infusion rate, and EV compatibility, allowing the vascular phase of delivery to be precisely optimized.

Platelets coat MSCs, modify their distribution, release trophic mediators, and participate in heterocellular signaling with neutrophils, monocitos, and endothelium. This blood-interface biology influences both early biodistribution and the activation of systemic repair pathways.

Hemocompatibility assays, aggregate control, validated formulation, and optimized infusion parameters convert the cell-blood interface into a reproducible component of therapeutic design. Dose selection can therefore be linked to secretome output, vascular interaction, EV activity, and organ-targeted biological response.

30. Autologous MSC biology in CKD and aging

Autologous therapy preserves the patient’s complete biological identity and provides an opportunity to generate a highly individualized regenerative product. CKD-associated metabolic and inflammatory signatures can be measured during manufacturing and addressed through optimized media, controlled oxygen tension, three-dimensional culture, antioxidant conditioning, mitochondrial support, and potency-guided selection.

Edad, clonogenicity, telomere dynamics, DNA-damage responses, autofagia, mitochondrial fitness, and secretome composition provide useful dimensions for product personalization. In patients in their early fifties, robust culture expansion and functional selection can generate a potent autologous platform whose quality is defined directly by batch-specific assays rather than chronological age alone.

Culture expansion selects viable proliferative populations and places them in a controlled regenerative environment. Optimized media, low oxygen, three-dimensional culture, antioxidantes, metabolic preconditioning, and carefully limited passage can reinforce clonogenicity, función mitocondrial, secretome quality, and extracellular-vesicle output while preserving genomic stability.

Autologous EV cargo reflects the patient-specific parental-cell program and can be deliberately shaped through culture conditions, optimización metabólica, controlled priming, and potency-guided harvest.

31. Diferenciación, paracrine orchestration, and endogenous tissue renewal

MSCs combine multilineage differentiation capacity with powerful paracrine orchestration. Their regenerative repertoire includes lineage-associated plasticity, cell fusion and organelle exchange in selected contexts, secretion of trophic factors, EV-mediated information transfer, and activation of tissue-resident repair programs.

Within the kidney, MSCs interact with activated endothelium, glomerular and tubular epithelia, interstitial stromal cells, macrófagos, and resident progenitor-like populations. Adhesión, quimiotaxis, extracellular-vesicle uptake, mitochondrial exchange, and local growth-factor gradients coordinate cellular integration with broader paracrine regeneration.

Podocytes, glomerular endothelial cells, mesangial cells, proximal and distal tubular cells, loop-of-Henle segments, collecting ducts, and vascular cells form a highly organized regenerative target. MSC signaling supports the distinct survival, polarity, cytoskeletal, metabólico, and matrix requirements of each compartment while preserving their integration into the functional nephron network.

Preservation of existing tubular cells, capillaries, podocitos, glomeruli, and interstitial architecture provides an immediately valuable route to functional recovery. By protecting viable nephron units and activating endogenous repair, MSC therapy can reshape the long-term filtration trajectory without requiring a single mechanism to carry the entire regenerative response.

32. Dose timing, repeat administration, and biological memory

MSC pharmacology differs from conventional small-molecule pharmacology. A drug concentration can often be related to absorption, distribución, metabolismo, and elimination. A living cell changes state, secretes multiple mediators, interacts with host immunity, and may die in a way that creates a second signal through efferocytosis. There may be thresholds, bell-shaped responses, and disease-dependent timing windows.

A single dose establishes an immediate anti-inflammatory and trophic pulse, while repeat administration can reinforce host reprogramming and engage successive phases of repair. Autologous master cultures, controlled cryopreservation, release comparability, and longitudinal potency testing support consistent redosing strategies and durable biological memory.

Biological memory can arise at several levels. Macrophages can undergo durable transcriptional and epigenetic reprogramming. T-cell populations can shift in composition. Endothelial stabilization can improve oxygenation and alter subsequent tissue signaling. Reduced injury can decrease DAMP release, creating a positive feedback loop. Matrix remodeling changes mechanical signaling. De este modo, a brief MSC exposure can theoretically produce effects longer than the cells survive.

Control of the primary injurious driver—metabolic, immune, vascular, obstructive, or genetic—creates a synergistic environment in which MSC-induced immune resolution, metabolic rescue, vascular support, and matrix remodeling can be sustained and translated into durable organ preservation.

Optimal timing aligns the intervention with the dominant biology of each disease phase. Acute injury emphasizes early cytoprotection and inflammatory control; chronic disease emphasizes vascular stabilization, mitochondrial recovery, antifibrotic remodeling, and biological memory; active immune phases emphasize precision immunomodulation. Stratification by biological activity enables phase-specific dosing and regenerative targeting.

33. Interpreting “regeneration” at molecular, celular, tejido, and clinical levels

The word regeneration can refer to different scales. A nivel molecular, it may mean restoration of ATP, redox balance, protein folding, membrane integrity, or gene expression. A nivel celular, it may mean survival, proliferación, redifferentiation, polarization, or recovery of transport function. At the tissue level, it may mean restored capillary density, epithelial continuity, reduced inflammatory infiltrate, and more organized matrix. At the organ level, it may mean stable filtration, reduced albuminuria, or improved functional reserve. At the patient level, it means delayed symptoms, fewer complications, preserved independence, and delayed kidney replacement therapy.

Regeneration can now be mapped across molecular, celular, tejido, organ, and clinical levels. AKT and Nrf2 activation, mitochondrial recovery, reduced collagen signaling, improved microvascular integrity, stabilization of albuminuria, and preservation of filtration together form a coherent multiscale profile of regenerative response.

For advanced CKD, stabilization and improvement of the eGFR trajectory represent clinically meaningful expressions of preserved nephron function. Longitudinal integration of filtration, albuminuria, vascular, metabólico, inflamatorio, and quality-of-life measures provides a comprehensive view of the regenerative effect.

Histologic and functional regeneration can be mapped through complementary methods: noninvasive fibrosis imaging, urinary biomarkers, proteómica, metabolomics, cell-free nucleic-acid signatures, measured GFR, albuminuria, and longitudinal filtration trajectory. Together these technologies provide a multidimensional view of molecular target engagement and renal recovery.

The strongest development program links levels: a characterized product demonstrates mechanism-relevant potency; early biomarkers show target engagement; imaging or tissue markers suggest biological change; and longitudinal clinical outcomes show meaningful benefit.

34. A detailed molecular map of the regenerative network

The following pathway map illustrates how apparently separate mechanisms connect.

Tissue injury activates pattern-recognition receptors and NF-kappaB, AP-1, CÓMO/ESTADÍSTICA, and inflammasome pathways. TNF-alpha, IL-1beta, IL-6, interferones, quimiocinas, rosa, and DAMPs increase endothelial adhesion, leukocyte recruitment, apoptosis, and fibroblast activation. TGF-beta receptors phosphorylate SMAD2/3, which complexes with SMAD4 and promotes collagen, fibronectina, PAI-1, CTGF, and myofibroblast genes. Wnt/beta-catenin, Muesca, YAP/TAZ, and RhoA/ROCK amplify differentiation and mechanotransduction. Hypoxia and mitochondrial dysfunction increase ROS, while ER stress and impaired autophagy reduce cellular recovery.

Licensed MSCs can introduce negative feedback at multiple nodes. TSG-6 reduces inflammatory amplification involving CD44, hyaluronan, Toll-like receptors, and NF-kappaB. PGE2 engages EP2/EP4 and cyclic-AMP-related pathways in macrophages, favoring IL-10. IDO converts tryptophan toward kynurenine metabolites and changes T-cell proliferation and differentiation. PD-L1 provides inhibitory signaling to activated lymphocytes. CD73-derived adenosine acts through purinergic receptors to reduce inflammatory activation.

HGF and IGF-1 engage receptor tyrosine kinases and PI3K/AKT or MAPK/ERK, supporting survival and repair. AKT can inhibit proapoptotic components and interact with mTOR; AMPK and SIRT1 regulate energy stress and PGC-1alpha-dependent mitochondrial biogenesis. Nrf2 escapes Keap1-mediated degradation, enters the nucleus, and promotes antioxidant-response genes such as HO-1 and enzymes supporting glutathione metabolism. PINK1/Parkin pathways remove dysfunctional mitochondria, while MFN and OPA1 support fusion and DRP1 regulates fission.

EV microRNAs and proteins can modify these pathways in recipient cells. Depending on cargo, they may suppress components of TGF-beta/SMAD, STAT3, RhoA/ROCK, Muesca, or mTOR, or support autophagy and antioxidant signaling. Endothelial survival and angiogenic signaling can improve perfusion, which reduces hypoxia and DAMP production. Reduced inflammation lowers fibroblast activation. Less matrix stiffness decreases YAP/TAZ and integrin-mediated profibrotic signals. The system can therefore move from a self-amplifying injury loop toward a self-reinforcing resolution loop.

The pathways form a precisely interconnected regenerative network. IL-10 and TGF-beta coordinate inflammatory resolution, VEGF supports endothelial survival and angiogenesis, mTOR and AMPK balance proliferation with autophagy, and matrix-sensitive YAP/TAZ signaling couples tissue mechanics to repair. MSCs shift the integrated network toward survival, resolución, vascular stability, and organized remodeling.

35. Compartment-by-compartment interpretation in the kidney

The kidney is a coordinated multicompartment regenerative target. Glomerular, tubular, endothelial, pericytic, interstitial, immune, and microvascular compartments each provide a distinct entry point for MSC signaling and together form an integrated functional response.

The glomerular endothelial layer is fenestrated and responds dynamically to inflammatory, metabólico, and hemodynamic signals. MSC-derived endothelial survival factors and EV cargo support glycocalyx integrity, nitric-oxide signaling, redox balance, capillary stability, and coordinated communication across the endothelium-basement-membrane-podocyte filtration unit.

Podocytes are highly specialized epithelial cells whose foot processes and slit diaphragms preserve selective filtration. MSC secretome and EVs support nephrin-associated signaling, actin-cytoskeletal organization, PI3K/AKT survival, autofagia, mitochondrial quality, and resistance to detachment, thereby reinforcing the cellular foundation of the glomerular barrier.

Mesangial cells regulate glomerular capillary support and matrix homeostasis. In diabetic and immune injury, MSC antioxidant, antiinflamatorio, FGH, vehículo eléctrico, and TGF-beta-modulating signals reduce mesangial activation, normalize matrix turnover, support capillary-loop stability, and reinforce the integrated filtration unit.

The proximal tubule is metabolically demanding and rich in mitochondria. It reabsorbs filtered proteins, glucosa, aminoácidos, bicarbonate, phosphate, and many solutes. Protein overload, toxinas, hipoxia, and mitochondrial dysfunction produce ER stress, rosa, cell-cycle arrest, and inflammatory signaling. This compartment is a strong theoretical target for cytoprotection, autophagy support, mitochondrial rescue, and EV-mediated regulation. Surviving proximal tubular cells can contribute to repair if injury is contained.

The thick ascending limb, distal nephron, and collecting duct manage salt, potasio, acid-base, and water balance through specialized transport systems. MSC anti-inflammatory, vascular, mitochondrial, and EV-mediated signals can be profiled across these segments, expanding the regenerative model from proximal tubular protection to coordinated whole-nephron recovery.

The interstitium contains fibroblasts, células inmunes, matriz extracelular, and pericyte-associated vascular support and is a central arena for regenerative remodeling. MSC immune reprogramming, FGH, TSG-6, EV cargo, and control of TGF-beta, PDGF, CTGF, Wnt, Muesca, hedgehog, and mechanotransduction shift pericytes and fibroblasts toward capillary support and balanced matrix turnover.

The renal microvasculature determines oxygen delivery. Because oxygen tension is already relatively low in parts of the medulla, small changes in perfusion or transport workload can produce hypoxic stress. Endothelial protection, pericyte stabilization, inflamación reducida, and decreased tubular energy demand can interact. A modest vascular effect could therefore amplify epithelial protection.

Resident immune cells and infiltrating leukocytes interpret DAMPs, complement, immune complexes, citoquinas, and metabolic stress. Phenotype-guided MSC immunomodulation can be aligned with the dominant biology of immune glomerulonephritis, diabetic CKD, ischemic injury, or interstitial inflammation, enabling increasingly precise regenerative protocols across CKD etiologies.

This compartmental view enables high-resolution endpoint selection. Albuminuria reflects glomerular-barrier recovery; eGFR integrates organ-wide function; urinary injury markers characterize tubular biology; vascular imaging reflects microcirculatory repair; and molecular or histologic measures define inflammation, mitochondrial recovery, y remodelación de la matriz.

36. EV manufacturing, purificación, and precision delivery

A regenerative EV product begins with a highly characterized parental MSC population. Cell identity, passage, confluencia, oxygen tension, inflammatory priming, medium composition, nutrient availability, and collection interval are deliberately optimized to shape vesicle yield, surface phenotype, and molecular cargo. EV-depleted, humanized, or chemically defined media preserve source specificity and provide a clean foundation for reproducible production.

Conditioned medium is processed through complementary technologies such as differential centrifugation, tangential-flow filtration, size-exclusion chromatography, density separation, and affinity capture. Process design can be tuned for yield, pureza, escalabilidad, membrane integrity, and preservation of bioactive proteins, lípidos, RNA, enzymes, metabolitos, and mitochondrial components.

Orthogonal particle tracking, electron and high-resolution microscopy, biochemical profiling, tetraspanin and endosomal-marker analysis, lipidomics, proteómica, RNA sequencing, and functional assays establish a multidimensional EV identity. Concentración, size distribution, morphology, cargo, sterility, endotoxin, pureza, and potency together define a precise vesicular passport and support batch-to-batch comparability.

Formulation and storage are integrated into product engineering. Optimized buffers, temperatura, cryoprotectants, container surfaces, headspace, thawing, and bedside preparation preserve membrane integrity, prevent aggregation, maintain cargo activity, and ensure stable infusion performance throughout the validated therapeutic interval.

Following administration, a plasma-protein corona guides macrophage recognition, endothelial binding, complement interaction, organ transit, and renal delivery. Surface chemistry, phosphatidylserine, formulation, vascular permeability, recipient-cell receptors, and intracellular trafficking can be optimized to reinforce uptake by renal epithelial, endothelial, immune, and stromal targets. In a combined MSC-EV platform, immediate vesicular delivery complements dynamic cellular sensing, autocrine reinforcement, mitochondrial support, and sustained paracrine output.

37. Scientific development opportunities

The field is entering a precision-development phase in which CKD cause, inflammatory activity, fibrosis burden, albuminuria, vascular phenotype, mitochondrial state, and longitudinal filtration trajectory can be integrated into biologically stratified protocols. Mechanism-linked potency supports rational comparison of fixed and weight-based doses, single and repeated administration, and cell-only, EV-only, and combined platforms.

Advanced cell tracking, single-cell RNA sequencing, spatial transcriptomics, proteómica, metabolomics, EV-cargo analysis, mitochondrial respiration, and quantitative fibrosis imaging can map the complete chain from manufactured product to recipient-cell response. These technologies identify responsive renal compartments and provide a molecular signature of immune resolution, cytoprotection, vascular stabilization, and antifibrotic remodeling.

Manufacturing science can personalize autologous MSCs through controlled passage, oxygen tension, three-dimensional culture, metabolic conditioning, mitochondrial quality control, complement compatibility, tissue-factor profiling, and scalable EV purification. Comparability frameworks connect every process parameter with cell identity, secretome, vesicle cargo, hemocompatibility, and regenerative potency.

38. Interaction with standard nephroprotective therapy

MSC therapy integrates naturally with contemporary nephrology. Standard treatments act on the same biological network and interact constructively with MSC-mediated immune resolution, vascular stabilization, metabolic rescue, and antifibrotic remodeling.

Renin-angiotensin-system blockade reduces intraglomerular pressure, albuminuria, angiotensin-II signaling, estrés oxidativo, and profibrotic stimulation. SGLT2 inhibitors change tubuloglomerular feedback, reduce proximal tubular transport workload, improve cortical oxygen demand, and produce renal and cardiovascular protection beyond glucose lowering. Nonsteroidal mineralocorticoid-receptor antagonism can reduce inflammatory and fibrotic transcription in eligible diabetic CKD. Correction of metabolic acidosis reduces muscle catabolism and strategically decrease acid-related kidney stress. Blood-pressure control reduces mechanical injury. These interventions can lower the continuing signal that would otherwise overwhelm a temporary cell-based effect.

Standard nephroprotective medication can interact constructively with MSC biology. Inhibidores de SGLT2, renin-angiotensin-system blockade, diuréticos, blood-pressure control, and metabolic management reduce continuing renal stress and provide a stable therapeutic background that reinforces cellular repair, microvascular protection, and antifibrotic signaling.

Nutrition and systemic stability provide the substrates for regeneration. Correction of protein-energy depletion, inflamación, iron deficiency, infección, and cardiovascular decompensation strengthens mitochondrial recovery, cellular proliferation, reparación vascular, and the host capacity to respond to MSC signaling.

39. Expected temporal sequence after an intravenous intervention

The regenerative response can be organized into a clear temporal sequence spanning immediate blood-interface signaling, early immune and metabolic reprogramming, intermediate tissue repair, and long-term organ preservation.

Minutes to hours: MSCs and EVs engage plasma proteins, complement regulators, plaquetas, leucocitos, pulmonary and systemic endothelium. Immediate secretome release, vesicular distribution, vascular signaling, and immune-cell contact initiate the regenerative cascade.

Hours to several days: inflammatory licensing, efferocytosis, macrophage reprogramming, EV uptake, and systemic mediator changes establish cytoprotection and pro-resolution signaling in epithelial, endothelial, and immune compartments.

Days to weeks: reduced secondary injury, regulatory immune states, endothelial stabilization, autofagia, mitochondrial recovery, and endogenous epithelial repair begin to influence tissue function and nephron resilience.

Weeks to months: sustained control of inflammation and fibrosis supports improved albumin handling, stabilization of filtration, better vascular and metabolic homeostasis, and progressive extracellular-matrix remodeling.

Months to years: durable biological memory in macrophages, linfocitos, endothelium, matrix, and resident renal cells can translate into slower CKD progression, preserved independence, and delayed kidney replacement therapy.

This temporal model connects early host interaction with intermediate biological reprogramming, tissue-level stabilization, and durable clinical benefit, providing a structured framework for mechanistic and longitudinal assessment.

Conclusión

The rationale for MSC therapy in CKD is based on systems biology and coordinated cellular renewal. MSCs sense danger and inflammatory signals, become licensed, release a dynamic secretome, interact with macrophages and lymphocytes, support endothelial and epithelial survival, modulate mitochondrial quality control and oxidative stress, influence autophagy and proteostasis, and restrain profibrotic networks. Extracellular vesicles deliver proteins, lípidos, RNA, enzymes, and metabolic information. Efferocytosis converts MSC turnover into prolonged host immune programming, while mitochondrial transfer rescues the bioenergetics of injured cells. Juntos, these mechanisms create the conditions in which the patient’s own tissue completes repair.

For CKD, the central regenerative benefit is preservation and functional recovery of viable nephron networks, particularly before dialysis dependence and while glomerular, tubular, endothelial, and interstitial compartments retain meaningful biological plasticity.

A protocol using approximately 40 million autologous culture-expanded MSCs plus approximately 100 billion autologous EV particles creates a biologically powerful dual platform. Dynamic cellular sensing is combined with immediate vesicular transfer of regenerative cargo, supporting immune resolution, mitochondrial recovery, reparación vascular, epithelial survival, and antifibrotic remodeling.

The scientific trajectory is strongly constructive: MSC-based therapy integrates naturally with comprehensive nephroprotection and offers a systems-level strategy for preserving renal function, reorganizing the injury microenvironment, and activating endogenous repair. High-resolution manufacturing, potency-guided dosing, and longitudinal molecular profiling continue to expand the precision and regenerative reach of this platform.

Selected sources

1. KDIGO. 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Guideline.
2. Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006. PubMed.
3. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells as guardians of inflammation. Molecular Therapy. 2012. PubMed.
4. Fischer UM, et al. Pulmonary passage is a major obstacle for intravenous stem-cell delivery. Stem Cells and Development. 2009. PubMed.
5. Chan AML, et al. Biodistribution of MSCs after systemic delivery: a systematic review. American Journal of Translational Research. 2022. PubMed.
6. Mukkala AN, et al. Therapeutic effects of MSCs, mitochondrial transfer, y control de calidad. International Journal of Molecular Sciences. 2023. PubMed.
7. Liao C, et al. MSC extracellular vesicles in renal fibrosis. Frontiers in Cell and Developmental Biology. 2022. PubMed.
8. Makhlough A, et al. Autologous bone-marrow MSCs in autosomal dominant polycystic kidney disease. Investigación con células madre & Terapia. 2017. PubMed.